Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
Tirzepatide on the NHS — UK access pathways
The honest picture of how tirzepatide (Mounjaro) is accessed on the NHS in 2026 — for type 2 diabetes and, under NICE TA1026, for weight management. Eligibility criteria, the service pathway, and realistic expectations. Educational only; confirm current NICE guidance and local commissioning with your GP.
The two NHS doors for tirzepatide
- Type 2 diabetes — Mounjaro (weekly injection). Licensed for type 2 diabetes and prescribed in NHS diabetes services where it fits NICE NG28 treatment criteria, typically after metformin and as an alternative to other GLP-1 agonists (semaglutide, liraglutide). The dual GLP-1 / GIP mechanism generally produces stronger HbA1c reduction and weight reduction than semaglutide head-to-head.
- Weight management — Mounjaro (NICE TA1026). NICE recommends tirzepatide for adult weight management within specialist NHS weight management services (typically tier 3), subject to eligibility criteria and local commissioning. Implementation is phased, with NHS England managing rollout to balance demand and capacity.
Mounjaro NHS eligibility under NICE TA1026
NICE TA1026 covers tirzepatide for adults with obesity within specialist NHS weight management services. The published criteria are:
- BMI ≥ 35 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease), or
- BMI ≥ 30 in defined ethnic groups (South Asian, Chinese, Black African, African-Caribbean, Middle Eastern) where lower BMI thresholds apply.
Treatment is licensed alongside a reduced-calorie diet and increased physical activity, and continued only while clinically appropriate. NICE has emphasised that NHS rollout will be phased over several years to manage capacity; in practice, local commissioning will determine whether eligible patients can start quickly or join a long waiting list.
Mounjaro NHS eligibility for type 2 diabetes
Mounjaro is licensed for type 2 diabetes under standard NHS diabetes pathways. The diabetes service / GP makes the choice between tirzepatide and other agents (semaglutide, liraglutide, DPP-4 inhibitors, SGLT2 inhibitors, insulin) based on HbA1c control needed, cardiovascular risk, weight reduction priority, comorbidities, and contraindications. Tirzepatide is generally preferred where additional weight reduction would be clinically valuable.
The realistic wait picture
For diabetes access, the wait is the standard GP / diabetes service wait — typically days to weeks. For weight management access (TA1026), the wait depends heavily on local tier-3 capacity and the phased NHS rollout schedule; some regions report multi-year waits, others have shorter pathways. This is the most common reason patients turn to private prescribers; see NHS vs private GLP-1 for an honest comparison.
How to get started
- For diabetes: book a routine GP appointment and ask whether tirzepatide fits your treatment plan. Have your most recent HbA1c, cardiovascular risk score, and current medication list ready.
- For weight management: ask your GP for a referral to your local specialist weight management service. Be prepared: your BMI, weight-related comorbidities, previous weight-loss attempts, and any contraindications will all be reviewed.
- Either pathway: raise contraindications yourself — personal or family history of medullary thyroid carcinoma, MEN2, history of pancreatitis, current pregnancy or pregnancy planning.
If you cannot get NHS tirzepatide
The two lawful UK alternatives are: (a) wait for your NHS pathway to open (TA1026 rollout is expanding over time), or (b) access via a GMC-registered private prescriber working with a regulated UK pharmacy — see private clinics — what good looks like and our how to check a UK pharmacy guide. Do not use social-media sellers, Telegram, or grey-market suppliers — the MHRA issued a Feb 2026 alert on falsified 15 mg Mounjaro KwikPens. See fake Mounjaro pens for the identifier guide and what to do if your pen looks wrong if you suspect a counterfeit.
What tirzepatide NHS access does not give you
- Faster appointments than your local service offers. The medicine is licensed; the bottleneck is the clinic appointment, not the medicine.
- Lifestyle bypass. Tirzepatide is licensed alongside diet and activity intervention. NHS services expect engagement with that as part of the treatment.
- Indefinite treatment without review. NICE requires periodic review of continued clinical benefit.